REBYOTA™ Prospective Registry is a study to collect information on patients who have received a treatment called REBYOTA™. This treatment is used to prevent a condition known as recurrent Clostridioides difficile infection (rCDI). rCDI is a stomach illness caused by bacteria that keep coming back. In this study, doctors will decide if a patient needs REBYOTA™ and then gather information from their medical records, but only if the patient agrees. The study will last for 6 months after the patient gets REBYOTA™. Information collected will include the patient's health history, any stomach illness events, symptoms, treatments, and hospital visits. There will be no new medicines or tests given as part of this study; it’s just about tracking existing care.
- Participation is for 6 months with no extra hospital visits required.
- Patients need to be 18 or older and have had rCDI.
- There are no new treatments or trials involved, just observation.